<?xml version="1.0" encoding="UTF-8"?>
<ref id="B35-biomedicines-08-00060">
 <label>35.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Conry</surname>
    <given-names>R.M.</given-names>
   </name>
   <name>
    <surname>Westbrook</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>McKee</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Norwood</surname>
    <given-names>T.G.</given-names>
   </name>
  </person-group>
  <article-title>Talimogene laherparepvec: First in class oncolytic virotherapy</article-title>
  <source>Hum. Vaccin. Immunother.</source>
  <year>2018</year>
  <volume>14</volume>
  <fpage>839</fpage>
  <lpage>846</lpage>
  <pub-id pub-id-type="doi">10.1080/21645515.2017.1412896</pub-id>
  <?supplied-pmid 29420123?>
  <pub-id pub-id-type="pmid">29420123</pub-id>
 </element-citation>
</ref>
